alzheimer semaglutide Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment novo nordisk semaglutide alzheimer trial

On-Treatment Analysis (If Everyone Stayed on Max Dose): CagriSema achieved 22.7% weight loss using trial-product estimand (assumes perfect adherence at max dose)

How the Pomegranate Health process works Getting started with Pomegranate Health follows a four-step process that mirrors most telehealth weight loss platforms

Inflammation is complex

June 2024 The Judicial Panel on Multidistrict Litigation has reassigned the Ozempic GLP-1RA MDL docket, which involves lawsuits claiming injuries from drugs like Ozempic and Mounjaro, to Judge Karen S

Research suggests that among those 40 or older, about 22.9% have knee osteoarthritis

Hungryroot Hungryroots meal delivery approach is designed for speed and convenience